UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
|
|
|
(Exact Name of Registrant as Specified in its Charter) |
|
|
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer |
|
|
|
(Address of Principal Executive Office) (Zip Code) |
Registrant’s telephone number, including area code:
|
Not Applicable |
|
(Former name or former address, if changed since last report) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of Each Class |
Trading Symbol |
Name of Each Exchange on Which Registered |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230-405) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|
Item 5.02 |
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On September 30, 2021, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), and Mr. Edward Borkowski, Executive Vice President, Operations of the Company, mutually agreed that Mr. Borkowski would separate from the Company, effective as of such date. Mr. Borkowski’s separation from the Company is a separation for “Good Reason” under his Employment Agreement with the Company, dated October 30, 2019, as amended, and Mr. Borkowski will receive the separation benefits provided therein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Date: October 1, 2021 |
|
THERAPEUTICSMD, INC. |
|
|
|
|
|
|
|
/s/ James C. D’Arecca |
|
|
|
James C. D’Arecca |
|
|
|
Chief Financial Officer |
Document and Entity Information |
Sep. 30, 2021 |
|---|---|
| Cover [Abstract] | |
| Amendment Flag | false |
| Entity Central Index Key | 0000025743 |
| Document Type | 8-K |
| Document Period End Date | Sep. 30, 2021 |
| Entity Registrant Name | TherapeuticsMD, Inc. |
| Entity Incorporation State Country Code | NV |
| Entity File Number | 001-00100 |
| Entity Tax Identification Number | 87-0233535 |
| Entity Address, Address Line One | 951 Yamato Road |
| Entity Address, Address Line Two | Suite 220 |
| Entity Address, City or Town | Boca Raton |
| Entity Address, State or Province | FL |
| Entity Address, Postal Zip Code | 33431 |
| City Area Code | (561) |
| Local Phone Number | 961-1900 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | TXMD |
| Security Exchange Name | NASDAQ |
| Entity Emerging Growth Company | false |